Натрийуретические пептиды - маркеры и факторы прогноза при хронической сердечной недостаточности
Аннотация
В большинстве эпидемиологических исследований диагноз хронической сердечной недостаточности (ХСН) выставляется на основании субъективных данных, что не позволяет с высокой достоверностью судить об истинной распространенности данного синдрома. Кроме того, диагностика ХСН на ранних стадиях заболевания сопряжена с определенными трудностями. В настоящее время объективным методом диагностики ХСН может быть определение концентрации натрийуретических пептидов, особенно мозгового натрийуретического пептида (brain natriuretic peptide, BNP), синтезируемого в кардиомиоцитах желудочков. BNP обладает высокими показателями чувствительности, специфичности и положительной прогностической ценности в отношении ХСН; по динамике концентрации данного гормона можно судить об эффективности проводимой терапии и титровать дозу лекарственных препаратов.Литература
1. Андреев Д. А., Батищев П. Н. Некоторые аспекты практического использования мозгового натрийуретического пептида в диагностических целях // Бюлл. НЦССХ им. А. Н. Бакулева РАМН. – 2004. – Т. 5, № 3. – С. 146–155.2. Андреев Д. А., Рыкова М. С. Натрийуретические пептиды В-типа при сердечной недостаточности // Клин. мед. – 2004. – № 6. – С. 4–8.
3. Баллюзек М. Ф., Гриненко Т. Н., Кветной И. М. Гормоны сердца в формировании сердечно-сосудистой патологии // Там же. – 2005. – № 11. – С. 4–12.
4. Бугримова М. А., Савина Н. М., Ваниева О. С., Сидоренко Б. А. Мозговой натрийуретический пептид как маркер и фактор прогноза при хронической сердечной недостаточности // Кардиология. – 2006. –№ 1. – С. 51–57.
5. Елисеев О. М. Натрийуретические пептиды. Эволюция знаний // Тер. арх. – 2003. – № 9. – С. 40–45.
6. Adams K. F., Mathur V. S., Gheorghiade M. et al. B-type natriuretic peptide from bench to bedside // Amer. Heart J. – 2003. – Vol. 145. – P. 34–46.
7. Ala-Kopsala M., Magga J., Peuhkurinen K. et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides // Clin. Chem. – 2004. – Vol. 50. – P. 1576–1588.
8. Anand I., Fisher L., Chiang Y. et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart fealure trial (Val-HeFT) // Circulation. – 2003. – Vol. 107. – P. 1276–1281.
9. Aspromonte N., Feola M., Scardovi A. et al. Early diagnosis of congestive heart failure: clinical utility of B-type natriuretic peptide testing associated with Doppler echocardiography // J. Cardiovasc. Med. – 2006. – Vol. 7. – P. 406–411.
10. Bay M., Kirk V., Parner J. et al. NT-proBNB: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function // Heart. – 2003. – Vol. 89. – P. 150–154.
11. Burnett J., Kao P., Hu D. et al. Atrial natriuretic peptide elevation in congestive heart failure in the human // Science. – 1986. – Vol. 231. – P. 1145–1147.
12. Cabanes L., RiChaud-Thiries S., Fulla Y. et al. B-type natriuretic peptide blood levels in the differential diagnosis of dyspnea // Chest. – 2001. – Vol. 120. – P. 131–138.
13. Cardarelli R., Lumicao T. G. B-type natriuretic peptide: a review of its diagnostic, prognostic, and therapeutic monitoring value in heart failure for primary care physicians // J. Amer. Board Family Practice. – 2003. – Vol. 16. – P. 327–333.
14. Cheng V., Kazanegra R., Garcia A. et al. A rapid bedside test for B-type natriuretic peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study // J. Amer. Coll. Cardiol. – 2001. – Vol. 37. – P. 386–391.
15. Cheng L., Kasanegra R., Gardetto N., Maisel A. A. Rapid bedside test for brain natriuretic peptide accurately predicts therapeutic response and clinical outcomes in patients admitted with decompensated heart failure // J. Amer. Coll. Cardiol. – 2000. – Vol. 35 (Suppl. A). – P. 171.
16. Choy A. M., Darbar D., Lang C. el al. Detection of left ventricular disfunction after acute myocardial infarction: comparison of clinical echographic and neurohormonal methods // Brit. Heart J. – 1994. – Vol. 72. – P. 16–22.
17. Clerico A., Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review // Clin. Chem. – 2004. – Vol. 50. – P. 33–50.
18. Clerico A., Lervasi G., Del Chicca M. G. et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure // J. Endocrinol. Invest. – 1998. – Vol. 21. – P. 170–179.
19. Collins S. P. Use of Nt-proBNP in the emergency department evaluation of shortness of breath: implications for clinical practice // Emerg. Med. Card. Research Educat. Group. – 2005. – Vol. 6. – P. 11–22.
20. Cowie M. R., Struthers A. D., Wood D. A. et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care // Lancet. – 1997. – Vol. 350. – P. 1349–1353.
21. Darbar L., Davidson N., Gilleepie N. et al. Diagnostic value of B-type natriuretic peptide concentration in patients with acute myocardial infarction // Amer. J. Cardiol. – 1996. – Vol. 78. – P. 284–287.
22. Davis M., Espiner E., Richards G. et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea // Lancet. – 1994. – Vol. 343. – P. 440–444.
23. Davis M., Richards A., Nicholls M. et al. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure // Circulation. – 2006. – Vol. 113. – P. 977–985.
24. De Lemos J., McGuire D. K., Drazner M. H. et al. B-type natriuretic peptide in cardiovascular disease // Lancet. – 2003. – Vol. 362. – P. 316–322.
25. Dirk J., van Veldhuisen, Genth-Zotz S. et al. Highversus low dose ACE inhibition in chronic heart fealure // J. Amer. Coll. Cardiol. – 1998. – Vol. 32. – P. 1811–1818.
26. Fleisher D., Espiner E., Richards G. et al. Rapid assay of plasma brain natriuretic peptide in the assessment of acute dyspnoea // NZ Med. J. – 1997. – Vol. 110. – P. 71–74.
27. Hara Y., Hamada M., Shigematsu Y. Effect of betablocker on left ventricular and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor // Jap. Circ. J. – 2000. – Vol. 64. – P. 365–369.
28. Januzzi J. L. Natriuretic peptide testing: A window into the diagnosis and prognosis of heart failure // Cleveland Clin. J. Med. – 2006. – Vol. 73. – P. 149–157.
29. Januzzi J. L., Camargo C. A., Anwaruddins et al. The N-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study // Amer. J. Card. – 2005. – Vol. 95. – P. 948–954.
30. Juffe A. S., Babuin L., Apple F. S. Biomarkers in acute cardiac disease // J. Amer. Coll. Cardiol. – 2006. – Vol. 48. – P. 1–11.
31. Karabulut A., Kaplan A., Aslan C. et al. The association between NT-proBNP levels, functional capacity and stage in patients with heart failure // Acta Cardiol. – 2005. – Vol. 60. – P. 631–638.
32. Kawai K., Hata K., Takaoka H. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during β-blocker therapy: A potential of hormone guided treatment // Amer. Heart J. – 2001. – Vol. 141. – P. 925–932.
33. Kikuta K., Yasue H., Yoshimura M. et al. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina // Ibid. – 1996. – Vol. 132. – P. 101–107.
34. Koglin J., Pehlivanli S., Schwaiblmair M. et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart fealure // J. Amer. Coll. Cardiol. – 2001. – Vol. 38. – P. 1934–1941.
35. Kohno M., Horio T., Yokokawa K. et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension // Amer. J. Med. – 1992. – Vol. 92. – P. 29–34.
36. Kohno M., Horio T., Yokokawa K. et al. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: changes during 1-year antihypertensive therapy with ACE inhibition // Ibid. – 1995. – Vol. 129. – P. 257–265.
37. Lubien E., DeMaria A., Krishnaswamy K. Utility of B-natriuretic peptide in diagnosing diastolic dysfunction // Circulation. – 2002. – Vol. 105. – P. 595–601.
38. Luchner A., Burnett J., Jougasaki M. et al. Augmentation of the cardiac natriuretic peptide by beta-receptor antagonism: Evidence from a population- based study // J. Amer. Coll. Cardiol. – 1998. – Vol. 32. – P. 1839–1844.
39. Luchner A., Hengstenberg C., Lowel H. et al. N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function // Hypertension. – 2002. – Vol. 39. – P. 99–104.
40. Lukowucz T., Fisher M., Hense H. et al. BNP as a marker of diastolic dysfunction in the general population: Importance of left ventricular hypertrophy // Eur. J. Heart Fail. – 2005. – Vol. 7. – P. 525–531.
41. Maisel A., Koon J., Krishnaswamy P. et al. Utility of B-natriuretic peptide as a rapid, point-ofcare test for screening patients undergoing echocardiography to determine left ventricular dysfunction // Amer. Heart J. – 2001. – Vol. 141. – P. 367–374.
42. McCullough P., Nowak R., McCord J. et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure // Circulation. – 2002. – Vol. 106. – P. 416–420.
43. McDonagh T., Robb S., Murdoch D. et al. Biochemical detection of left-ventricular systolic dysfunction // Lancet. – 1998. – Vol. 351. – P. 9–13.
44. Morita E., Yasue H., Yoshimura M. Increased plasma levels of brain natriuretic peptide in patient with acute myocardial infarction // Circulation. – 1993. – Vol. 88. – P. 82–91.
45. Morwani J. G., McAlfine H., Kennedy N., Struthers A. D. Plasma BNP as an indicator for angiotensin converting enzyme inhibition after myocardial infarction // Lancet. – 1993. – Vol. 341. – P. 1109–1113.
46. Mucoyama M., Nakao K., Hosoda K. et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system? // J. Clin. Invest. – 1991. – Vol. 87. – P. 828–831.
47. Mueller T., Gegenhuber A., Poelz W., Haltmeyer M. Head-to-head comparison of the diagnostic utility of BNP and proBNP in symptomatic and asymptomatic structural heart disease // Clin. Chim. Acta. – 2004. – Vol. 341. – P. 41–48.
48. Mukoyama M., Nakao K., Saito Y. et al. Human brain natriuretic peptide a novel cardiac hormone // Lancet. – 1990. – Vol. 335. – P. 801–802.
49. Murdoch D., McDonagh T., Byrne J. et al. Titration of vasodilatator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy // Amer. Heart J. – 1999. – Vol. 138. – P. 1126–1130.
50. Nagaya N., Nishikimi T., Goto Y. Plasma brain natriuretic peptide levels associated with progressive ventricular remodeling after acute myocardial infarction // Clin. Sci. – 1999. – Vol. 96. – P. 129–136.
51. Neil C. Davidson, Abdelwahab A. Naas, Jacqueline K. et al. Comparison of Atrial natriuretic peptide, B-Type natriuretic peptide, and N-Terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction // Amer. J. Cardiol. – 1996. – Vol. 77. – P. 828–831.
52. Nishikimi T., Yoshihara F., Ishikava K. et al. Relation between left ventricular geometry and natriuretic peptide levels in essential hypertension // Hypertension. – 1996. – Vol. 28. – P. 22–30.
53. Omland T., Aakvaag A., Bonarjee V. et al. Plasma BNP as an indicator of left ventricular function and long term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N terminal proatrial natriuretic peptide // Circulation. – 1996. – Vol. 93. – P. 1963–1969.
54. Richards A., Doughty R., Nicholls M. for Australia– New Zeland Heart Failure Group. Plasma Nterminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction // J. Amer. Coll. Cardiol. – 2001. – Vol. 37. – P. 1781–1787.
55. Richards M., Nicholls M., Espener E. et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease // Ibid. – 2006. – Vol. 47. – P. 61–64.
56. Sarasso G., Airodli L., Frongia E. et al. Plasma levels of brain natriuretic peptide in hypertension patients are related to left ventricular remodeling patterns // Eur. Heart J. – 2000. – Vol. 21 (Suppl.). – P. 619.
57. Schnabel R., Lubos E., Rupprecht H. et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study // J. Amer. Coll. Cardiol. – 2006. – Vol. 47. – P. 552–558.
58. Sheth T., Parker T., Block A. et al. Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart fealure // Amer. J. Cardiol. – 2002. – Vol. 90. – P. 5.
59. Sumida H., Hirofumi Y., Michihiro Y., Ken O. Comparison of secretion patterns between A-type and B-type Brain natriuretic peptides in patients with old myocardial infarction // J. Amer. Coll. Cardiol. – 1995. – Vol. 25. – P. 1105–1110.
60. Sun T., Wang L., Zhang Y. Prognostic value of B-type natriuretic peptide in patients with acute coronary syndrome // Arch. Med. Res. – 2006. – Vol. 37. – P. 502–505.
61. Takeda T., Kohno M. Brain natriuretic peptide in hypertension // Hypertens. Res. – 1995. – Vol. 18, № 4. – P. 259–266.
62. Tanaka M., Ishihara F., Ishikawa F. et al. Exercise induced secretion of brain natriuretic peptide in essential hypertension and normal subjects // Ibid. – 1995. – Vol. 18. – P. 152–166.
63. Troughton R. W., Frampton C. M., Yandle T. G. et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations // Lancet. – 2000. – Vol. 355. – P. 1126–1130.
64. Tsutamoto T., Wada A., Maeda K. et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart fealure // Circulation. – 1997. – Vol. 96. – P. 509–516.
65. Wallen T., Landahi S., Hedner T. et al. Brain natriuretic peptide in an elderly population // J. Intern Med. – 1997. – Vol. 242. – P. 307–311.
66. Watanabe I., Tani S., Washio T. et al. // Int. Heart J. – 2005. – Vol. 46. – P. 1007–1014.
67. Weber M., Hamm C. Role of B-type natriuretic peptide (BNP) and Nt-proBNP in clinical routine // Heart. – 2006. – Vol. 92. – P. 843–849.
68. Weber M., Hausen M., Arnold R. et al. Prognostic value of N-terminal pro-B-type natriuretic peptide for conservatively and surgically treated patients with aortic valve stenosis // Ibid. – 2006. – Vol. 92. – P. 1639–1644.
69. Wu A. H., Packer M., Smith A. et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study // Clin. Chem. – 2004. – Vol. 50. – P. 867–873.
70. Yoshibayashi M., Kamiya T., Saito Y. et al. Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: marked and rapid increase after birth // Eur. J. Endocrinol. – 1995. – Vol. 133. – P. 207–209.
71. Yoshimura M., Mizuno Y., Nakamura M. et al. Btype natriuretic peptide as a marker of the effects of enalapril 4 in patients with heart fealure // Amer. J. Med. – 2002. – Vol. 12, № 9. – P. 716–720.
72. Zaphiriou A., Robb S., Murray-Thomas T. et al. The diagnostic accuracy pf plasma BNP and N-pro- BNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptidein study // Eur. J. Heart Fail. – 2005. – Vol. 7. – P. 537–541.
